Financial Performance - The company's operating revenue for 2024 was CNY 795,288,308.90, a decrease of 2.63% compared to 2023 [22]. - Net profit attributable to shareholders for 2024 was CNY 206,791,017.22, down 18.55% from the previous year [22]. - The basic earnings per share for 2024 was CNY 0.25, reflecting a decline of 19.35% compared to 2023 [23]. - The weighted average return on equity decreased to 9.40% in 2024, down 3.33 percentage points from 2023 [23]. - The net cash flow from operating activities for 2024 was CNY 177,925,777.36, a decrease of 19.80% from 2023 [22]. - Total assets at the end of 2024 were CNY 2,982,390,050.39, an increase of 1.04% compared to the end of 2023 [22]. - The net assets attributable to shareholders increased by 6.08% to CNY 2,271,891,202.71 at the end of 2024 [22]. - The company reported a net profit of CNY 112,480,834.45 in the first quarter of 2024, with a significant drop in the fourth quarter resulting in a loss of CNY 22,194,656.44 [26]. - Non-recurring gains and losses totaled CNY 27,910,357.77 for 2024, compared to CNY 10,685,665.36 in 2023 [28]. - The company achieved operating revenue of 795.29 million yuan, a year-on-year decrease of 2.63% [33]. - The net profit attributable to shareholders was 206.79 million yuan, down 18.55% year-on-year [33]. Research and Development - R&D investment reached 100.42 million yuan, accounting for 12.63% of operating revenue, with a year-on-year increase of 28.65% [33]. - The company has established a research and development team of 495 members, including various educational backgrounds, to enhance innovation capabilities [36]. - The company’s R&D investment for the reporting period was CNY 100.42 million, accounting for 12.63% of operating revenue, representing a year-on-year increase of 28.65% [94]. - The number of R&D personnel is 495, making up 40.61% of the total workforce [75]. - The company plans to increase R&D investment, with projected expenditures of CNY 78.06 million and CNY 100.42 million for 2023 and 2024, respectively, representing 9.56% and 12.63% of revenue [116]. - The company is committed to developing innovative drugs with independent intellectual property rights, transitioning from generic to innovative pharmaceuticals [113]. - The company plans to increase investment in the development of synthetic biology technology, peptide drugs, RNA, oligonucleotides, and mid-molecule drugs [89]. Market and Industry Trends - The global pharmaceutical market is projected to grow from approximately $1.6 trillion in 2023 to about $2.2 trillion by 2028, with a compound annual growth rate of 6.6% [38]. - The market for expiring patented drugs is estimated to grow from $51 billion in 2023 to $99 billion by 2028, providing significant opportunities for generic drug companies [38]. - The aging population in China is a key driver for the pharmaceutical market, with the population aged 65 and above expected to grow from 140 million in 2014 to 220 million by 2024, representing approximately 15.64% of the total population [40]. - China's total healthcare expenditure increased from 3.5 trillion yuan in 2014 to 9.1 trillion yuan in 2023, indicating a significant growth in healthcare spending [40]. - The global CRO market size grew from $53.91 billion in 2018 to $82.11 billion in 2023, with a compound annual growth rate (CAGR) of 8.8%, and is projected to reach $106.45 billion by 2026 [41]. - The global CDMO market reached $146.29 billion in 2023 and is expected to grow to approximately $295.95 billion by 2033, with a CAGR of 7.3% from 2024 to 2033 [42]. Corporate Governance - The company has confirmed that all board members attended the board meeting, ensuring governance compliance [4]. - The company has appointed Tianjian Accounting Firm as its auditor, with specific auditors named for the reporting period [21]. - The board of directors and supervisory board have adhered to legal requirements and company regulations in their operations and decision-making processes [120]. - The company has maintained independence from its controlling shareholder in terms of business, personnel, assets, and financial matters [120]. - The company has established an investor relations management system to enhance communication with investors and address their inquiries effectively [122]. - The company has established specialized committees, including an audit committee, nomination committee, remuneration and assessment committee, and strategic committee [137]. Environmental Responsibility - The company has invested RMB 23,579,500 in environmental protection during the reporting period [159]. - The company has established a wastewater treatment system with a capacity of 1,050 tons per day and an organic waste gas RTO incineration device with a capacity of 38,000 cubic meters per hour [161]. - The company has implemented an environmental self-monitoring plan, with all monitored pollutants meeting discharge standards [164]. - The company has a complete environmental risk emergency mechanism and has filed an emergency response plan for sudden environmental pollution events [163]. - There were no administrative penalties related to environmental issues during the reporting period [165]. Shareholder Information - The company plans to distribute a cash dividend of RMB 1 per 10 shares to all shareholders, totaling approximately RMB 82.83 million (including tax) based on the current total share capital of 830,297,145 shares, after accounting for the repurchased shares [6]. - The total number of shares increased from 593,069,389 to 830,297,145 after a capital reserve conversion and cash dividend distribution [193]. - The largest shareholder, Zheng Zhiguo, holds 420,433,703 shares, representing 50.64% of the total shares [198]. - The top five customers accounted for 56.34% and 56.08% of total revenue in 2023 and 2024, indicating a high customer concentration risk [117]. - The company’s total number of ordinary shareholders increased from 30,806 to 42,377 during the reporting period [196]. Strategic Initiatives - The company is focusing on expanding its overseas sales teams, particularly in Europe, Japan, the United States, and South Korea, to strengthen market presence [33]. - The company emphasizes a strategy of integrating intermediates, specialty APIs, and formulations to enhance competitiveness and ensure sustainable development [37]. - The company aims to accelerate the transition from raw materials to formulation development and promote internationalization of formulations [89]. - The company plans to leverage the expiration of numerous innovative drug patents in the coming years to enhance its market position [109]. - The company is committed to increasing R&D investment and improving processes to ensure technological and cost leadership [110].

国金证券股份有限公司 关于浙江奥翔药业股份有限公司 国金证券股份有限公司（以下简称"保荐机构"）作为浙江奥翔药业股份有限 公司（以下简称"奥翔药业"、"公司"、"发行人"）2022 年非公开发行股票的保荐 机构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所股票上市规则》、 《上海证券交易所上市公司自律监管指引第 1 号—规范运作》以及《上市公司监 管指引第 2 号—上市公司募集资金管理和使用的监管要求》等相关规定履行持续 督导职责，就奥翔药业使用闲置募集资金进行现金管理相关事项进行了审慎核查， 核查具体情况如下： 一、 本次使用闲置募集资金进行现金管理概况 使用闲置募集资金进行现金管理的核查意见 （一）现金管理目的 为提高公司及子公司资金使用效率，在不影响募集资金项目建设和公司正常 经营的情况下，合理利用部分闲置募集资金进行现金管理，增加资金收益，为公 司及股东获取更多的投资回报。 （二）现金管理投资金额 公司及子公司拟使用最高额不超过 5,000 万元人民币的闲置募集资金进行现 金管理，在上述额度及决议有效期内，资金可循环滚动使用。 （三）资金来源 1、资金来源的一般情况 公司 2022 年度非公 ...

一、本次募集资金基本情况 国金证券股份有限公司 关于浙江奥翔药业股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国金证券股份有限公司（以下简称"保荐机构"）作为浙江奥翔药业股份有 限公司（以下简称"奥翔药业"、"公司"、"发行人"）2022 年非公开发行股票的 保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所股票上市 规则》、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》以及《上市 公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》等相关规定履 行持续督导职责，就奥翔药业及全资子公司浙江麒正药业有限公司（以下简称"麒 正药业"、"子公司"）拟使用不超过人民币 15,000.00 万元的闲置募集资金暂时补 充流动资金，期限自公司董事会审议通过之日起 12 个月内有效相关事项进行了 审慎核查，核查具体情况如下： 经中国证券监督管理委员会《关于核准浙江奥翔药业股份有限公司非公开发 行股票的批复》（证监许可〔2022〕2237 号）核准，奥翔药业非公开发行人民币 普通股（A 股）股票 21,754,288 股，发行价为每股人民币 22.29 元，募集资金总 额 4 ...

关于浙江奥翔药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 委托单位：浙江奥翔药业股份有限公司 审计单位：天健会计师事务所（特殊普通合伙） 联系电话：0571-88216888 1、 专项审计报告 2、 附表 目 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表……………第 3—3 页 목록 ： 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕9081 号 浙江奥翔药业股份有限公司全体股东: 我们接受委托,审计了浙江奥翔药业股份有限公司(以下简称奥翔药业公司) 2024 年度财务报表,包括 2024年 12月 31 日的合并及母公司资产负债表,2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表,以及财务报表附注,并出具了审计报告。在此基础上,我们审计了后 附的奥翔药业公司管理层编制的 2024年度《非经营性资金占用及其他关联资金 往来情况汇总表》(以下简称汇总表)。 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 306,636,220.57, representing a 1.90% increase compared to CNY 300,914,417.10 in the same period last year[3]. - Net profit attributable to shareholders was CNY 119,199,188.77, up 5.97% from CNY 112,480,834.45 year-on-year[3]. - The company reported a diluted earnings per share of CNY 0.14, unchanged from the previous year[3]. - Net profit for Q1 2025 was CNY 119,199,188.77, up 6.1% from CNY 112,480,834.45 in Q1 2024[16]. - The company reported a total comprehensive income of CNY 119,869,435.30 for Q1 2025, compared to CNY 112,485,569.05 in Q1 2024[16]. - Basic and diluted earnings per share remained stable at CNY 0.14 for both Q1 2025 and Q1 2024[16]. Cash Flow and Operating Activities - The net cash flow from operating activities decreased significantly by 92.42%, amounting to CNY 2,046,387.30, primarily due to increased payments for goods compared to the previous year[6]. - Cash flow from operating activities generated a net amount of CNY 2,046,387.30 in Q1 2025, down from CNY 26,983,529.17 in Q1 2024[19]. - The company experienced a net cash outflow from financing activities of CNY 15,083,389.51 in Q1 2025, an improvement from CNY 19,759,399.18 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,120,558,712.61, a 4.63% increase from CNY 2,982,390,050.39 at the end of the previous year[4]. - The company's current assets reached RMB 1,836,403,912.68, up from RMB 1,709,169,547.87, indicating an increase of about 7.43%[10]. - The accounts receivable increased significantly to RMB 326,512,713.44 from RMB 192,215,593.45, representing a growth of approximately 69.9%[10]. - The inventory decreased to RMB 384,355,661.51 from RMB 400,949,911.46, showing a decline of about 4.15%[10]. - The total liabilities of the company were RMB 748,785,133.12, compared to RMB 710,498,847.68, marking an increase of approximately 5.4%[12]. - The owner's equity totaled RMB 2,371,773,579.49, up from RMB 2,271,891,202.71, reflecting an increase of about 4.4%[12]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,806[7]. - The largest shareholder, Zheng Zhiguo, holds 50.64% of the shares, totaling 420,433,703 shares[7]. Other Financial Metrics - The weighted average return on equity was 5.11%, a slight decrease of 0.01 percentage points from 5.12% in the previous year[3]. - The company recognized non-recurring gains of CNY 2,408,407.73 from government subsidies related to its normal business operations[5]. - Research and development expenses rose to CNY 28,303,999.30 in Q1 2025, compared to CNY 23,250,646.98 in Q1 2024, marking a 21.7% increase[15]. - The company's cash and cash equivalents stood at RMB 1,104,801,644.13, slightly up from RMB 1,096,287,944.72, indicating a marginal increase of about 0.78%[10]. - The short-term borrowings rose to RMB 290,088,710.70 from RMB 270,309,905.42, which is an increase of approximately 7.3%[12]. - The company's retained earnings increased to RMB 973,667,050.41 from RMB 872,321,733.96, representing a growth of about 11.6%[12]. - The total equity attributable to the owners of the parent company increased by approximately 4.4% from RMB 2,271,891,202.71 to RMB 2,371,773,579.49[12]. - The company recorded a foreign exchange gain of CNY 3,875,717.81 in Q1 2025, compared to a loss of CNY 691,997.96 in Q1 2024[20].

国金证券股份有限公司 关于浙江奥翔药业股份有限公司 2024 年持续督导年度报告书 | 保荐机构名称 | 国金证券股份有限公司 | | --- | --- | | 注册地址 | 成都市青羊区东城根上街 号 95 | | 办公地址 | 成都市青羊区东城根上街 号成证大厦 楼 95 16 | | 法定代表人 | 冉云 | | 保荐代表人姓名 | 余波、樊石磊 | | 联系电话 | 021-68826021 | | 上市公司名称 | 浙江奥翔药业股份有限公司 | | --- | --- | | 注册地址 | 浙江省化学原料药基地临海园区东海第四大道 号 5 | | 办公地址 | 浙江省化学原料药基地临海园区东海第四大道 5 号 | | 法定代表人 | 郑志国 | | 联系人 | 应晓晨 | | 联系电话 | 0576-85589367 | 浙江奥翔药业股份有限公司（以下简称"奥翔药业"、"发行人"、"上市 公司"、"公司"）于 2017 年 5 月首次公开发行 A 股股票并上市。国金证券股 份有限公司（以下简称"国金证券"）作为奥翔药业首次公开发行股票的保荐机 构，持续督导期至 2019 年 12 月 31 日止。 ...

目 录 浙江奥翔药业股份有限公司全体股东： 我们接受委托，审计了浙江奥翔药业股份有限公司（以下简称奥翔药业公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后 附的奥翔药业公司管理层编制的 2024 年度《非经营性资金占用及其他关联资金 往来情况汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 本报告仅供奥翔药业公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为奥翔药业公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕9081 号 为了更好地理解奥翔药业公司 2024 年度非经营性资金占用及其他关联资金 往来情况，汇 ...

目 录 二、关于募集资金年度存放与使用情况的专项报告 ……………第 3—12 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕9080 号 浙江奥翔药业股份有限公司全体股东： 我们鉴证了后附的浙江奥翔药业股份有限公司（以下简称奥翔药业公司）管 理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供奥翔药业公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为奥翔药业公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 奥翔药业公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》（证监会公告〔2022〕15 号）和《上海证券交易所上市公司自律监管 指引第 1 号——规范运作（2023 年 12 月修订）》（上证发〔2023〕193 号）的 规定编制《关于募集资金年度存放与使用情况的专项报告》，并保证其内容真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 三、注册会计师的责任 一、募集资金年 ...

国金证券股份有限公司 关于浙江奥翔药业股份有限公司 2022 年非公开发行股票持续督导保荐总结报告书 经中国证券监督管理委员会证监许可〔2022〕2237 号文核准，并经上海证 券交易所同意，浙江奥翔药业股份有限公司（以下简称"奥翔药业"、"发行人"、 "上市公司"、"公司"）向特定对象非公开发行人民币普通股（A 股）股票 21,754,288 股，募集资金总额 484,903,079.52 元。本次发行的新增股份已于 2023 年 2 月 3 日在中国证券登记结算有限责任公司上海分公司办理完成登记托管手 续。 国金证券股份有限公司（以下简称"国金证券"）作为奥翔药业 2022 年非 公开发行股票的保荐机构，负责奥翔药业的持续督导工作，截至 2024 年 12 月 31 日，持续督导期已届满。截止目前，奥翔药业 2022 年非公开发行的募集资金 尚未使用完毕，保荐机构将对其募集资金使用情况继续履行持续督导义务。根据 《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第 11 号——持续督导》等法规、规范性文件相 关要求，出具本保荐总结报告书。 一、保荐机构及保 ...